UTHR United Therapeutics Corp
2,041
$266.22
$5.71
(2.19%)
| Watchers | 2,041 |
| 52-Wk Low | $204.44 |
| 52-Wk High | $266.65 |
| Market Cap | $11.81B |
| Volume | 686,557.00 |
| 52-Wk High | $266.65 |
| 52-Wk Low | $204.44 |
United Therapeutics Corporation Reports First Quarter 2024 Financial ResultsBusiness Wire • 7 days ago
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024...
Share to Feed
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American...
United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The shares were sold...
Related Stocks: UTHR...
StockNews.com upgraded shares of United Therapeutics (NASDAQ:UTHR - Free Report) from a buy rating to a strong-buy rating in a research note released on Wednesday.
A number of other equities research...
Related Stocks: UTHR...
First Citizens Bank & Trust Co. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the...
United Therapeutics motion for restraining order over Liquidia's Yutrepia denied...
United Therapeutics motion for restraining order over Liquidia's Yutrepia denied...
United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 325 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an...